The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Studies Examine Impact of Poverty, Race, Ethnicity in Patients with SLE

New Studies Examine Impact of Poverty, Race, Ethnicity in Patients with SLE

October 17, 2017 • By Elizabeth Hofheinz, MPH, MEd

  • Tweet
  • Email
Print-Friendly Version / Save PDF
mantinov / shutterstock.com

mantinov / shutterstock.com

To correctly address a problem, one must have a handle on its nuances—a clear understanding of what is linked and how. And thus far, when it comes to lupus, we haven’t reached the point of understanding those intricacies.

You Might Also Like
  • New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE
  • Cardiovascular Disease Rate Differs Between SLE Patients of Different Races, Ethnicities
  • Racial Disparities Result in Unprecedented Differences in Outcomes for SLE Patients
Explore This Issue
October 2017

Things are heading in the right direction, however, with two new studies that get us much closer to untangling the relationships among lupus, poverty, race and ethnicity.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Edward Yelin, PhD, is professor emeritus at the University of California, San Francisco. His work, “A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in SLE,” was recently published in Arthritis & Rheumatology.1

Dr. Yelin says, “We already know that racial and ethnic minorities are more likely to be diagnosed with lupus than are Caucasians. However, after the onset of the disease, it is not race or ethnicity that primarily drives the differences in outcomes. There is a solid history of literature indicating that it is poverty or other socioeconomic issues.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The question, says Dr. Yelin, is “Why?”

Dr. Yelin

Dr. Yelin

In an attempt to tease out the answer to this and other questions, Dr. Yelin and his colleagues followed 783 lupus patients from 2003 to 2015, focusing on the extent of disease damage experienced by each participant.

“One question that arose was, ‘Is it poverty itself that poses the problem, or is it something to do with the personality of those who tend to be poor?’ We postulated that the number of years a lupus patient had been poor has a strong relationship with how much disease damage they had suffered. Although we could not randomize people to poverty, we were able to observe whether people who left poverty had better outcomes—and indeed they did.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Length of Time in Poverty Matters

Elaborating on this sociological dose-response relationship between poverty and lupus-related damage, Dr. Yelin notes, “We found that the longer people lived in poverty, the more disease damage they sustained. Those who were able to permanently transition out of poverty did have similar increases in damage as those who were never in poverty, but it was not as severe as those who remained poor.”

Given that lifting large numbers of patients out of poverty is a supremely challenging, long-term goal, Dr. Yelin and his colleagues wanted to find out what else was going on. Perhaps there were things occurring at a micro, daily level that could be amenable to improvements. And although they found them, the fact is that there are no simple answers.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Diagnosis, disparity, impact, income, inequality, Lupus, patient care, poverty, pregnancy, racial, Research, Rheumatic Disease, rheumatology, risk, socioeconomic, Stress, study, Systemic lupus erythematosusIssue: October 2017

You Might Also Like:
  • New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE
  • Cardiovascular Disease Rate Differs Between SLE Patients of Different Races, Ethnicities
  • Racial Disparities Result in Unprecedented Differences in Outcomes for SLE Patients
  • Infection Rates for Patients with SLE on Immunosuppressive Drugs

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)